4/15/2014

300,000 Orion A-shares converted into B-shares

ORION CORPORATION      STOCK EXCHANGE RELEASE 15 APRIL 2014 at 8.45  a.m. EEST     

In accordance with Section 3 of the Articles of Association of Orion Corporation, 300,000 A-shares have been converted into 300,000  B-shares. The conversion has been entered into the Trade Register on 15 April 2014.

The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 41,722,816 A-shares and  99,535,012 B-shares.

  
Orion Corporation

  

Olli Huotari
SVP, Corporate Functions
Jari Karlson
CFO

                                                                       
                                                                       

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.